References
- Research S Anti-VEGF market size is projected to reach USD 13.54 Billion by 2030, growing at a CAGR of 1.02%: straits research. GlobeNewswire News Room. 2022. [cited May 2, 2023]. Available at: https://www.globenewswire.com/news-release/2022/07/21/2484044/0/en/Anti-VEGF-Market-Size-is-projected-to-reach-USD-13-54-Billion-by-2030-growing-at-a-CAGR-of-1-02-Straits-Research.html
- Sharma A, Reddy P, Kuppermann BD, et al. Biosimilars in ophthalmology: Is there a big change on the horizon? OPTH. 2018;12:2137–2143.
- Anon. FDA approves samsung bioepis and biogen’s BYOOVIZTM (SB11), LUCENTIS® biosimilar (ranibizumab-nuna) | Biogen. [cited Sep 29, 2022]. Available at: https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11
- Sharma A, Kondo M, Iwahashi C, et al. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2023 Feb;37(2):200–202. doi: 10.1038/s41433-022-02246-5
- Sharma A, Kumar N, Kuppermann B, et al. Ophthalmic biosimilars: Lessons from India. Indian J Ophthalmol. 2019;67(8):1384. doi: 10.4103/ijo.IJO_430_19
- Sharma A, Kumar N, Parachuri N, et al. Ranibizumab biosimilar (razumab) vs innovator ranibizumab (lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). Eye (Lond). 2022;36(5):1106–1107. doi: 10.1038/s41433-021-01616-9
- Medical Lead - Ophthalmology, Medical Services, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India., S, S, Ma K, Medical Services, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India. Real-life clinical effectiveness of razumab® (world’s first biosimilar Ranibizumab) in wet age- related macular degeneration, diabetic macular edema, and retinal vein occlusion: a retrospective pooled analysis. IJOES 2018:p. 377–383.
- Sharma S, Khan MA, Chaturvedi A, et al. Real-life clinical effectiveness of razumab® (the world’s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241(1):24–31. doi: 10.1159/000488602
- Sharma S, Khan M, Chaturvedi A, et al. A multicenter, retrospective study (RE-ENACT 2) on the use of razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther. 2020;9(1):103–114. doi: 10.1007/s40123-019-00228-7
- Sharma S. RE-ENACT 2 study investigators group, Khan M, Chaturvedi A. A Multicenter, retrospective study (RE-ENACT 2) on RazumabTM (world’s first biosimilar ranibizumab) in retinal vein occlusion. Ophthalmol Ther. 2020;9:625–639.
- Chakraborty D, Mondal S, Boral S, et al. Biosimilar versus InnovAtor MoLecule of ranibizumab in neovascular age-related macular degeneration (the balance trial): real-world evidence. Clin Ophthalmol. 2023 Apr 8;17:1067–1076.
- Colin DD CDSCO panel asked intas limited to submit the protocol for the phase IV clinical trial of Ranibizumab for the new indication. 2022. [cited May 2, 2023]. Available at: https://medicaldialogues.in/news/industry/pharma/cdsco-panel-approves-intas-ranibizumab-for-new-indication-retinopathy-of-pre-maturity-in-preterm-infants-94350
- Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139(1):68. doi: 10.1001/jamaophthalmol.2020.5053
- Anon. Lucentis biosimilars approved in the UK and Korea. [cited May 2, 2023]. Available at: https://www.gabionline.net/biosimilars/news/lucentis-biosimilars-approved-in-the-uk-and-korea
- Apsangikar P, Ghadge P, Naik M, et al. Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (wet) age-related macular degeneration. Clin Ophthalmol. 2021;15:3087–3095. doi: 10.2147/OPTH.S307746
- Singh R, Chauhan R, Saxena A, et al. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis ® in patients with neovascular age-related macular degeneration. Indian J Ophthalmol. 2022;70(8):3008–3014. doi: 10.4103/ijo.IJO_2118_21
- Anon. A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degeneration-. UMIN clinical trials registry 2017. [cited Nov 1, 2020]. Available at: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034245
- Yoon CK, Oh J, Bae K, et al. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial. Plos One. 2022;17(11):e0275611. doi: 10.1371/journal.pone.0275611
- Watch BM BioCND to develop lucentis® biosimilar. big molecule watch 2016. [cited May 2, 2023]. Available at: https://www.bigmoleculewatch.com/2016/12/21/biocnd-to-develop-lucentis-biosimilar/
- https://www.drugs.com/medical-answers/eylea-patent-expire-3571144/#:~:text=The%20current%20patent%20expiry%20dates,11%2C%202032%20(for%202)
- Woo SJ, Bradvica M, Vajas A, et al. Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. JAMA Ophthalmol. 2023 Jun;8:e232260. doi: 10.1001/jamaophthalmol.2023.2260
- Ranibizumab biosimilar - pharma research BIO/qilu pharmaceuticals. cited Jul 8, 2023. https://adisinsight.springer.com/drugs/800048500
- Editor B. Phase III study for Alvotech’s AVT06 (biosimilar aflibercept) to proceed in India. Pearce IP 2022. [cited May 2, 2023]. Available at: https://www.pearceip.law/2022/10/09/phase-iii-study-for-alvotechs-avt06-biosimilar-aflibercept-to-proceed-in-india/
- Chitgupi RA Phase III randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity between SCD411 and eylea® in subjects with neovascular age-related macular degeneration. [cited May 2, 2023]. Available at: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45552
- Shah CA Phase III, prospective, randomized, parallel group, double-blind, multicentre study to compare the efficacy, safety, and immunogenicity of lupin’s aflibercept with eylea® in patients with neovascular age-related macular degeneration. [cited May 2, 2023]. Available at: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=72922